



Maffia, P. and Cirino, G. (2017) Targeting inflammation to reduce cardiovascular disease risk. *British Journal of Pharmacology*, 174(22), pp. 3895-3897. (doi:[10.1111/bph.14039](https://doi.org/10.1111/bph.14039))

There may be differences between this version and the published version. You are advised to consult the publisher's version if you wish to cite from it.

This is the peer-reviewed version of the following article: Maffia, P. and Cirino, G. (2017) Targeting inflammation to reduce cardiovascular disease risk. *British Journal of Pharmacology*, 174(22), pp. 3895-3897, which has been published in final form at [10.1111/bph.14039](https://doi.org/10.1111/bph.14039). This article may be used for non-commercial purposes in accordance with [Wiley Terms and Conditions for Self-Archiving](#).

<http://eprints.gla.ac.uk/148593/>

Deposited on 22 September 2017

EDITORIAL

Targeting inflammation to reduce cardiovascular disease risk

Pasquale Maffia^{1,2,3} and Giuseppe Cirino³

¹*Centre for Immunobiology, Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom,*

²*Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom,* ³*Department of Pharmacy, University of Naples Federico II, Naples, Italy*

Correspondence Pasquale Maffia, Centre for Immunobiology, Institute of Infection, Immunity and Inflammation, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom. E-mail: Pasquale.Maffia@glasgow.ac.uk and Giuseppe Cirino, Department of Pharmacology, University of Naples Federico II, Naples, Italy. E-mail: cirino@unina.it

This joint themed issue of the British Journal of Pharmacology and the British Journal of Clinical Pharmacology stems from a joint British Pharmacological Society - Italian Society of Pharmacology symposium held at the 37th National Congress of the Italian Society of Pharmacology in Naples (Italy) from 27 to 30 October 2015.

LINKED ARTICLES

This article is part of a themed section on Targeting inflammation to reduce cardiovascular disease risk

Abbreviations

apoE^{-/-}, apolipoprotein-E deficient mice; AT, adipose tissue; ATL, aspirin-triggered lipoxin A4; CANTOS, Canakinumab Anti-inflammatory Thrombosis Outcomes Study; COX, cyclooxygenase; CVD, cardiovascular diseases; DPP4, dipeptidyl peptidase 4; H₂S, hydrogen sulphide; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; mPGES-1, microsomal prostaglandin E synthase-1; NO, nitric oxide; NK, natural

killer; PAR2, proteinase-activated receptor 2, PG, prostaglandin; PVAT, perivascular adipose tissue; tNSAIDs, traditional nonsteroidal anti-inflammatory drugs; Tsk mice, tight-skin mice.

Cardiovascular diseases (CVD) are the major cause of morbidity and mortality in Western society and are expected to be the main cause of death globally in the near future (WHO, 2011). Basic research data strongly support a pivotal role played by inflammatory and immune mechanisms in CVD and studies in animal models have shown that specific immune-inflammatory pathways could be targeted for therapeutic utility. However, the translation of this knowledge to humans is still in the early stages (Welsh *et al.*, 2017).

New and selective immune therapies are already in use for the treatment of autoimmune diseases and large clinical trials have just been published or are currently evaluating the effect of several of these treatments on atherosclerosis and related pathologies. The outcome of these studies is likely to lead to new approaches in the management of vascular inflammation.

This joint *British Journal of Pharmacology* and *British Journal of Clinical Pharmacology* themed issue assembles scientists that study cardiovascular inflammation over a broad range of topics. The aim is to provide an up-to-date overview of the current understanding of inflammatory and immune mechanisms in CVD, to summarise the current clinical picture regarding the use of anti-inflammatory drugs in cardiovascular medicine and to discuss future directions towards more specific immune therapies.

The themed issue is introduced by Paul Welsh *et al.* (Welsh *et al.*, 2017). The authors provide an overview of the key therapeutic targets in the treatment of vascular inflammation, placing basic research in a wider clinical perspective. Following the publication of the review article, data from the Phase III [Canakinumab](#) Anti-inflammatory Thrombosis Outcomes Study (CANTOS: <https://clinicaltrials.gov/ct2/show/NCT01327846>) have been published, showing that canakinumab - a monoclonal antibody against [IL-1 \$\beta\$](#) - in combination with standard therapy reduces recurrent cardiovascular events in people with a prior myocardial infarction and high levels of circulating C-reactive protein (Ridker *et al.*, 2017). This is the first demonstration in a large, randomized, double blind, placebo-controlled Phase III study that using anti-cytokine-based therapies may be a viable approach for secondary prevention of atherosclerosis-related CVD. This is particularly relevant given that the use of traditional nonsteroidal anti-inflammatory drugs (tNSAIDs) and coxibs alike is limited by cardiovascular toxicity as comprehensively discussed by Carlo Patrono (Patrono, 2016). He provides an overview of the cardiovascular effects of [cyclooxygenase](#) (COX)-2 inhibitors, with a focus on the mechanisms contributing to the clinical readouts of COX-2 inhibition.

Several other key immune-mediated mechanisms in CVD could represent future options for therapeutic targeting and are discussed in detail in the current issue. T cell-mediated immune responses play a key role in ischaemic heart disease and in acute viral myocarditis (Stephenson *et al.*, 2016). The authors propose that the development of novel specific diagnostic biomarkers could help to identify at an early stage patients who may benefit from immunomodulatory therapies. Andy Sage and Ziad Mallat (Sage and Mallat, 2017) discuss therapeutic strategies to target adaptive immunity to reduce atherosclerosis progression, such as regulatory T cell enhancing therapies, B cell depletion and vaccine-based approaches. Their work is complemented by the review from Amanda Foks and Johan Kuiper, where the authors discuss the therapeutic potential to control atherosclerosis through targeting a large variety of costimulatory and inhibitory immune checkpoint proteins (Foks and Kuiper, 2017). In addition, the role of cytotoxic lymphocytes such as natural killer cells, CD8⁺ T cells, natural killer (NK) T cells, $\gamma\delta$ -T cells and human CD4⁺CD28⁻ T cells in the development of atherosclerosis and unstable atheromas is reviewed (Kyaw *et al.*, 2017).

Inflammation and hypercholesterolemia are linked in a cycle where an excess of [cholesterol](#) accumulating in the vessel wall layers induces immune-inflammatory response(s), which in turn increase cholesterol deposition and accelerate pathology formation and development. Catapano *et al.* provide an overview of the crosstalk between inflammation and lipid metabolism, suggesting that the clinical impact of lipid-lowering drugs on inflammation is proportional to the reduction of low-density lipoprotein cholesterol (LDL-C) levels (Catapano *et al.*, 2017). Concurrently, Iqbal *et al.* discuss the negative impact of systemic and vascular inflammation on the healthy metabolism and function of high-density lipoprotein cholesterol (HDL-C) (Iqbal *et al.*, 2017).

The contribution of perivascular adipose tissue (PVAT) to vascular inflammation has gained significant attention recently. Adipocytes, immune cells and fibroblasts within adipose tissue secrete a broad range of adipokines exerting endocrine or paracrine effects on the cardiovascular system. Among them, the role of [adiponectin](#) in cardiovascular pathogenesis, its capacity to regulate the crosstalk between adipose tissue and the cardiovascular system and its role as a biomarker in CVD are comprehensively discussed (Woodward *et al.*, 2016).

In the final review article, Cirino *et al.* discuss the role of gasotransmitters in vascular physiology and pathology (Cirino *et al.*, 2017). The authors summarize what is currently known on the interconnection between [nitric oxide](#) (NO) and [hydrogen sulfide](#) (H₂S),

pointing out that addressing the molecular mechanisms underlying the interaction of these two gas mediators may lead to the development of new therapeutic approaches.

The themed issue ends with five original research contributions. The work by Roviezzo *et al.* analyses the effect of [proteinase-activated receptor 2](#) (PAR2) on aortic contraction in fibrotic tight-skin (Tsk) mice (Roviezzo *et al.*, 2017). Petri *et al.* investigated the effect of [aspirin-triggered lipoxin A4](#) (ATL) and its receptor [Fpr2](#) on atherosclerosis development and progression, showing anti-atherogenic effects of ATL in apolipoprotein-E (apoE)^{-/-} mice (Petri *et al.*, 2017). The selective [Mas receptor](#) agonist AVE0991 was shown to exert anti-atherosclerotic effects by affecting monocyte/macrophage recruitment to the perivascular space in experimental atherosclerosis (Skiba *et al.*, 2016). Esposito *et al.* demonstrated that the dipeptidyl peptidase 4 (DPP4) inhibitor [sitagliptin](#) preserved diastolic function in a rat model of heart failure with preserved ejection (Esposito *et al.*, 2016). Finally, the effect of inhibitors of COX-2 and microsomal [prostaglandin E synthase-1](#) (mPGES-1) enzyme, which catalyses the formation of [PGE₂](#) from COX-derived [PGH₂](#), was compared *in vitro* on human vascular tone (Ozen *et al.*, 2017).

In summary, this joint themed issue of *British Journal of Pharmacology* and *British Journal of Clinical Pharmacology* will provide readers with a review of the key inflammatory and immune mechanisms in cardiovascular pathologies, the role of lipid and gas mediators in cardiovascular inflammation and the use of conventional anti-inflammatory drugs in cardiovascular medicine. In addition, the interplay between vascular inflammation and lipid metabolism, together with recent clinical trials targeting immune pathways for CVD prevention are comprehensively discussed. Great advances have been made in our understanding of immune mechanisms underlying CVD. Translation of these findings in clinical practice has only just begun; however, promising recent results may pave the way for the design of novel tissue- and or disease-specific immunomodulatory approaches to tackle the challenge posed by CVD on public health.

Nomenclature of Targets and Ligands

Key protein targets and ligands in this article are hyperlinked to corresponding entries in <http://www.guidetopharmacology.org>, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Southan *et al.*, 2016), and are permanently archived in the Concise Guide to PHARMACOLOGY 2015/16 (Alexander *et al.*, 2015).

Acknowledgements

We thank all authors who contributed to this Research Topic. This work was funded by the British Heart Foundation grants PG/12/81/29897 and RE/13/5/30177; the European Commission Marie Skłodowska-Curie Individual Fellowships 661369; the EPSRC grant EP/L014165/1; and the Tenovus Scotland PROJECT S15/24.

Conflict of Interest

The authors wish to acknowledge that they are co- authors of the articles by Welsh *et al.* (2017), Cirino *et al.* (2017) and Roviezzo *et al.* (2016) in this issue. They have also co-authored papers with Andrew Sage, Ziad Mallat, Liberato Berrino, Francesco Rossi, Antonella De Angelis and Konrad Urbanek.

References

Alexander SP, Fabbro D, Kelly E, Marrion N, Peters JA, Benson HE, *et al.* (2015). The Concise Guide to PHARMACOLOGY 2015/16: Catalytic receptors. *Br J Pharmacol* 172(24): 5979-6023.

Alexander SP, Fabbro D, Kelly E, Marrion N, Peters JA, Benson HE, *et al.* (2015). The Concise Guide to PHARMACOLOGY 2015/16: Enzymes. *Br J Pharmacol* 172(24): 6024-109.

Alexander SP, Kelly E, Marrion N, Peters JA, Benson HE, Faccenda E, *et al.* (2015). The Concise Guide to PHARMACOLOGY 2015/16: Overview. *Br J Pharmacol* 172(24): 5729-43.

Catapano AL, Pirillo A, Norata GD (2017). Vascular inflammation and low-density lipoproteins: is cholesterol the link? A lesson from the clinical trials. *Br J Pharmacol* 2016 Mar 30. doi: 10.1111/bph.13805. [Epub ahead of print].

Cirino G, Vellecco V, Bucci M (2017). Nitric oxide and hydrogen sulfide: the gasotransmitter paradigm of the vascular system. *Br J Pharmacol* 2017 Apr 13. doi: 10.1111/bph.13815. [Epub ahead of print].

Esposito G, Cappetta D, Russo R, Rivellino A, Ciuffreda LP, Roviezzo F, *et al.* (2016). Sitagliptin reduces inflammation, fibrosis and preserves diastolic function in a rat model of heart failure with preserved ejection fraction. *Br J Pharmacol* 2016 Dec 6. doi: 10.1111/bph.13686. [Epub ahead of print].

Foks AC, Kuiper J (2017). Immune checkpoint proteins: exploring their therapeutic potential to regulate atherosclerosis. *Br J Pharmacol* 2017 Mar 30. doi: 10.1111/bph.13802. [Epub ahead of print].

Iqbal F, Baker WS, Khan MI, Thukuntla S, McKinney KH, Abate N, *et al.* (2017). Current and future therapies for addressing the effects of inflammation on HDL cholesterol metabolism. *Br J Pharmacol* 2017 Mar 22. doi: 10.1111/bph.13743. [Epub ahead of print].

Kyaw T, Peter K, Li Y, Tipping P, Toh BH, Bobik A (2017). Cytotoxic lymphocytes and atherosclerosis: significance, mechanisms and therapeutic challenges. *Br J Pharmacol* 2017 May 4. doi: 10.1111/bph.13845. [Epub ahead of print].

Ozen G, Gomez I, Daci A, Deschildre C, Boubaya L, Teskin O, *et al.* (2017). mPGES-1 inhibitor reduces human vascular tone by increasing PGI(2) : a safer alternative to COXIBs.

Br J Pharmacol 2017 Jul 3. doi: 10.1111/bph.13939. [Epub ahead of print].

Patrono C (2016). Cardiovascular effects of cyclooxygenase-2 inhibitors: a mechanistic and clinical perspective. Br J Clin Pharmacol 82(4):957-64.

Petri MH, Laguna-Fernandez A, Arnardottir H, Wheelock CE, Perretti M, Hansson GK, *et al.* (2017). Aspirin-triggered lipoxin A4 inhibits atherosclerosis progression in apolipoprotein E(-/-) mice. Br J Pharmacol 2017 Jan 10. doi: 10.1111/bph.13707. [Epub ahead of print].

Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, *et al.* (2017). Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med 2017 Aug 27. doi: 10.1056/NEJMoa1707914. [Epub ahead of print].

Roviezzo F, Brancaleone V, Mattera Iacono V, Bertolino A, De Cunto G, Vellecco V, *et al.* (2016). Proteinase activated receptor-2 counterbalances the vascular effects of endothelin-1 in fibrotic tight-skin mice. Br J Pharmacol 2016 Sep 14. doi: 10.1111/bph.13618. [Epub ahead of print].

Sage AP, Mallat Z (2017). Readapting the adaptive immune response - therapeutic strategies for atherosclerosis. Br J Pharmacol 2017 Jan 4. doi: 10.1111/bph.13700. [Epub ahead of print].

Skiba DS, Nosalski R, Mikolajczyk TP, Siedlinski M, Rios FJ, Montezano AC, *et al.* (2016). Anti-atherosclerotic effect of the angiotensin 1-7 mimetic AVE0991 is mediated by inhibition of perivascular and plaque inflammation in early atherosclerosis. Br J Pharmacol 2016 Dec 9. doi: 10.1111/bph.13685. [Epub ahead of print].

Southan C, Sharman JL, Benson HE, Faccenda E, Pawson AJ, Alexander SP *et al.* (2016). The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. Nucl Acids Res 44: D1054-1068.

Stephenson E, Savvatis K, Mohiddin SA, Marelli-Berg FM (2016). T-cell immunity in myocardial inflammation: pathogenic role and therapeutic manipulation. Br J Pharmacol 2016 Sep 2. doi: 10.1111/bph.13613. [Epub ahead of print].

Welsh P, Grassia G, Botha S, Sattar N, Maffia P (2017). Targeting inflammation to reduce cardiovascular disease risk: a realistic clinical prospect? Br J Pharmacol 2017 Apr 13. doi: 10.1111/bph.13818. [Epub ahead of print].

Woodward L, Akoumianakis I, Antoniadou C (2016). Unravelling the adiponectin paradox: novel roles of adiponectin in the regulation of cardiovascular disease. Br J Pharmacol 2016

Sep 15. doi: 10.1111/bph.13619. [Epub ahead of print].

World Health Organization (WHO) (2011). Global status report on noncommunicable diseases 2010. ISBN: 978 92 4 156422 9.